Interestingly, although ALK-inhibition therapy with second- and third-generation drugs has shown some potential in ALK-positive, non-CNS lymphomas [78], none of the identified patients received ALK-inhibition therapy. Here, ALK is linked to primary central nervous system lymphoma.